Cargando...
Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry
Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no sequence homology to TPO, was developed to avoid immunogenicity...
Gardado en:
| Publicado en: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540503/ https://ncbi.nlm.nih.gov/pubmed/32311075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16658 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|